209 related articles for article (PubMed ID: 28894400)
41. Tigecycline to treat Stenotrophomonas maltophilia ventilator-associated pneumonia in a trauma intensive care unit as a result of a drug shortage: A case series.
Farrar JE; Garner KM; Swanson JM; Magnotti LJ; Croce MA; Wood GC
J Clin Pharm Ther; 2020 Aug; 45(4):836-839. PubMed ID: 32406951
[TBL] [Abstract][Full Text] [Related]
42. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer.
Ansari SR; Hanna H; Hachem R; Jiang Y; Rolston K; Raad I
Cancer; 2007 Jun; 109(12):2615-22. PubMed ID: 17487860
[TBL] [Abstract][Full Text] [Related]
43. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.
Toleman MA; Bennett PM; Bennett DM; Jones RN; Walsh TR
Emerg Infect Dis; 2007 Apr; 13(4):559-65. PubMed ID: 17553270
[TBL] [Abstract][Full Text] [Related]
44. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for
Sarzynski SH; Warner S; Sun J; Matsouaka R; Dekker JP; Babiker A; Li W; Lai YL; Danner RL; Fowler VG; Kadri SS
Open Forum Infect Dis; 2022 Feb; 9(2):ofab644. PubMed ID: 35097154
[TBL] [Abstract][Full Text] [Related]
45. Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens.
Çıkman A; Parlak M; Bayram Y; Güdücüoğlu H; Berktaş M
Afr Health Sci; 2016 Mar; 16(1):149-52. PubMed ID: 27358626
[TBL] [Abstract][Full Text] [Related]
46. Molecular epidemiology and characteristics of 16 cases with Stenotrophomonas maltophilia bacteraemia in pediatric Intensive Care Units.
Motamedifar M; Heidari H; Yasemi M; Sedigh Ebrahim-Saraie H
Ann Ig; 2017; 29(4):264-272. PubMed ID: 28569336
[TBL] [Abstract][Full Text] [Related]
47. Temperature, pH and Trimethoprim-Sulfamethoxazole Are Potent Inhibitors of Biofilm Formation by Stenotrophomonas maltophilia Clinical Isolates.
Biočanin M; Madi H; Vasiljević Z; Kojić M; Jovčić B; Lozo J
Pol J Microbiol; 2017 Dec; 66(4):433-438. PubMed ID: 29319523
[TBL] [Abstract][Full Text] [Related]
48. Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study.
Nair AP; Sasi S; Al Maslamani M; Al-Khal A; Chacko K; Deshmukh A; Abukhattab M
Cureus; 2022 Mar; 14(3):e23263. PubMed ID: 35449666
[TBL] [Abstract][Full Text] [Related]
49. In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant
Wu J; Zhang G; Zhao Q; Wang L; Yang J; Cui J
Infect Drug Resist; 2023; 16():6005-6015. PubMed ID: 37705512
[TBL] [Abstract][Full Text] [Related]
50. Real-world, multicentre evaluation of the incidence and risk factors for non-susceptible Stenotrophomonas maltophilia isolates.
Jones BM; Wagner JL; Chastain DB; Bookstaver PB; Stover K; Lin J; Matson H; White N; Motesh M; Bland CM
J Glob Antimicrob Resist; 2022 Mar; 28():282-287. PubMed ID: 35150899
[TBL] [Abstract][Full Text] [Related]
51. Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen.
Penzak SR; Abate BJ
Pharmacotherapy; 1997; 17(2):293-301. PubMed ID: 9085321
[TBL] [Abstract][Full Text] [Related]
52. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.
Cho SY; Lee DG; Choi SM; Park C; Chun HS; Park YJ; Choi JK; Lee HJ; Park SH; Choi JH; Yoo JH
BMC Infect Dis; 2015 Feb; 15():69. PubMed ID: 25887489
[TBL] [Abstract][Full Text] [Related]
53. The Burden of Bloodstream Infections due to
Cai B; Tillotson G; Benjumea D; Callahan P; Echols R
Open Forum Infect Dis; 2020 May; 7(5):ofaa141. PubMed ID: 32462047
[TBL] [Abstract][Full Text] [Related]
54. Stenotrophomonas maltophilia keratitis treated with trimethoprim-sulfamethoxazole.
Díez-Álvarez L; Lumbreras-Fernández B; García-Pérez JL
Arch Soc Esp Oftalmol; 2015 Nov; 90(11):539-41. PubMed ID: 26008926
[TBL] [Abstract][Full Text] [Related]
55. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.
Poulos CD; Matsumura SO; Willey BM; Low DE; McGeer A
Antimicrob Agents Chemother; 1995 Oct; 39(10):2220-3. PubMed ID: 8619571
[TBL] [Abstract][Full Text] [Related]
56. [Investigation of the presence of class 1, 2, 3 integrons and their relationships with antibiotic resistance in clinical Stenotrophomonas maltophilia isolates].
Usta E; Eroğlu C; Yanık K; Karadağ A; Güney AK; Günaydın M
Mikrobiyol Bul; 2015 Jan; 49(1):35-46. PubMed ID: 25706729
[TBL] [Abstract][Full Text] [Related]
57. Minimal Inhibitory Concentration of Ceftazidime and Co-trimoxazole for Stenotrophomonas Maltophilia using E-test.
Jamali F; Boroumand MA; Yazdani F; Anvari MS; Pourgholi L; Mahfouzi S; Khak M
J Glob Infect Dis; 2011 Jul; 3(3):254-8. PubMed ID: 21887057
[TBL] [Abstract][Full Text] [Related]
58. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods.
Nicodemo AC; Araujo MR; Ruiz AS; Gales AC
J Antimicrob Chemother; 2004 Apr; 53(4):604-8. PubMed ID: 14973153
[TBL] [Abstract][Full Text] [Related]
59. Global prevalence and distribution of antibiotic resistance among clinical isolates of Stenotrophomonas maltophilia: A systematic review and meta-analysis.
Dadashi M; Hajikhani B; Nazarinejad N; Noorisepehr N; Yazdani S; Hashemi A; Hashemizadeh Z; Goudarzi M; Fatemeh S
J Glob Antimicrob Resist; 2023 Sep; 34():253-267. PubMed ID: 36906172
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of resistance genes and antibiotic resistance profile among
Baseri Z; Dehghan A; Yaghoubi S; Razavi S
New Microbes New Infect; 2021 Nov; 44():100943. PubMed ID: 34631110
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
